OBJECTIVE: Women with early-stage, ER + breast cancer are recommend to receive genomic profiling tests, such as the 21-gene Recurrence Score (RS) test, to guide treatment decisions. We examined test- and treatment-related information discussed and the associations between RS categories and aspects of communication during patient-oncologist clinical encounters. METHODS: As part of a larger trial, clinical encounters (N = 46) were audiorecorded and coded for 1) RS- and treatment-related information, 2) shared decision making, 3) patient active participation, and 4) oncologist patient-centered communication. We examined differences by RS category using mixed models, adjusting for nesting within oncologist. RESULTS: Patients with a high RS were more likely to receive a chemotherapy recommendation (p < .01), hear about the risks/side effects of chemotherapy (p < .01), and offer their preferences (p = .02) than those with intermediate or low RS. Elements of shared decision making increased with RS. Oncologist patient-centered communication (M = 4.09/5, SD = .25) and patient active participation (M = 3.5/4, SD = 1.0) were high across RS. CONCLUSION: Findings suggest that disease severity, rather than clinical uncertainty, impact treatment recommendations and shared decision making. PRACTICE IMPLICATIONS: Oncologists adjust test- and treatment-related information and shared decision making by disease severity. This information provides a framework to inform decision making in complex cancer and genomics settings.
OBJECTIVE: Women with early-stage, ER + breast cancer are recommend to receive genomic profiling tests, such as the 21-gene Recurrence Score (RS) test, to guide treatment decisions. We examined test- and treatment-related information discussed and the associations between RS categories and aspects of communication during patient-oncologist clinical encounters. METHODS: As part of a larger trial, clinical encounters (N = 46) were audiorecorded and coded for 1) RS- and treatment-related information, 2) shared decision making, 3) patient active participation, and 4) oncologist patient-centered communication. We examined differences by RS category using mixed models, adjusting for nesting within oncologist. RESULTS: Patients with a high RS were more likely to receive a chemotherapy recommendation (p < .01), hear about the risks/side effects of chemotherapy (p < .01), and offer their preferences (p = .02) than those with intermediate or low RS. Elements of shared decision making increased with RS. Oncologist patient-centered communication (M = 4.09/5, SD = .25) and patient active participation (M = 3.5/4, SD = 1.0) were high across RS. CONCLUSION: Findings suggest that disease severity, rather than clinical uncertainty, impact treatment recommendations and shared decision making. PRACTICE IMPLICATIONS: Oncologists adjust test- and treatment-related information and shared decision making by disease severity. This information provides a framework to inform decision making in complex cancer and genomics settings.
Authors: Susan Eggly; Lauren M Hamel; Tanina S Foster; Terrance L Albrecht; Robert Chapman; Felicity W K Harper; Hayley Thompson; Jennifer J Griggs; Richard Gonzalez; Lisa Berry-Bobovski; Rifky Tkatch; Michael Simon; Anthony Shields; Shirish Gadgeel; Randa Loutfi; Haythem Ali; Ira Wollner; Louis A Penner Journal: Patient Educ Couns Date: 2016-12-27
Authors: Suzanne C O'Neill; Claudine Isaacs; Calvin Chao; Huei-Ting Tsai; Chunfu Liu; Bola F Ekezue; Nandini Selvam; Larry G Kessler; Marc D Schwartz; Tania Lobo; Arnold L Potosky Journal: J Natl Compr Canc Netw Date: 2015-10 Impact factor: 11.908
Authors: Janice P Tzeng; Deborah Mayer; Alice R Richman; Isaac Lipkus; Paul K Han; Carmina G Valle; Lisa A Carey; Noel T Brewer Journal: Cancer Date: 2010-04-15 Impact factor: 6.860
Authors: Nancy K Janz; Patricia A Wren; Laurel A Copeland; Julie C Lowery; Sherry L Goldfarb; Edwin G Wilkins Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Heather L Kane; Michael T Halpern; Linda B Squiers; Katherine A Treiman; Lauren A McCormack Journal: CA Cancer J Clin Date: 2014-09-08 Impact factor: 508.702